Discovery and Classification
For a long time, the pathogen was hidden under the term "non-A, non-B hepatitis." The virus was discovered in 1983 through an unprecedented scientific step—an experiment involving self-inoculation. Soviet scientist M.S. Balayan and his co-authors used fecal extracts obtained from nine patients with unexplained hepatitis for their research, which allowed them to isolate a new infectious agent.
In modern taxonomy, the pathogen belongs to the family Hepeviridae, classified into the separate genus Hepevirus.
Morphology and Genome
The pathogen is a non-enveloped virion, meaning it completely lacks an outer lipid envelope. It has a spherical shape with a particle diameter ranging from 27 to 34 nm. The protein capsid is organized with icosahedral symmetry.
The viral genetic material is represented by a single-stranded, positive-sense RNA molecule (+ssRNA). This genome encodes several viral proteins critical for its life cycle:
- RNA-dependent RNA polymerase (essential for copying genetic material);
- Papain-like protease (participates in viral protein maturation);
- Transmembrane protein (performs the key function of viral entry into a susceptible target cell).
Epidemiology
The primary transmission mechanism is fecal-oral, with the waterborne route (consumption of contaminated drinking water) playing a dominant role. Geographically, the disease is distributed very unevenly worldwide, though historically a very high frequency of outbreaks has been noted in Central Asian countries.
The source of infection includes not only sick humans. Active circulation of the virus among wild and domestic animals—specifically pigs, cattle, and birds—has been proven. This indicates a pronounced zoonotic potential of the virus, allowing direct transmission of the pathogen from an infected animal to a human.
Clinical Presentation
The incubation period (the time from infection to the appearance of the first symptoms) lasts from 2 to 6 weeks. The classic clinical picture consists of two main components: generalized intoxication syndrome and signs of moderate liver damage. Notably, the jaundice typical of other hepatitis types occurs significantly less frequently in this infection.
Following recovery, a lasting immunity is established. For the general population, the disease prognosis is considered favorable, but a critical risk group exists.
In pregnant women, the infection can take extremely severe forms. Mortality in this group is not uncommon. The leading causes of death are rapidly developing hemorrhagic syndrome and acute renal failure.
Diagnosis, Treatment, and Prevention
Microbiological diagnosis relies on two main testing methods:
- Serological method (ELISA): performed on blood serum or plasma. Detection of specific anti-HEV IgM antibodies confirms the acute phase of infection. Detection of anti-HEV IgG indicates past disease and established immunity.
- Molecular genetic method (PCR): used in the acute phase to detect viral RNA (HEV RNA). Stool samples and blood serum serve as test materials.
No specific antiviral treatment has been approved. Standard therapy is limited to symptomatic and supportive measures. Special attention is given to pregnant women: due to the high risk of severe disease, the administration of specific immunoglobulins is indicated.
Non-specific prevention is based on sanitary and hygienic measures, primarily ensuring access to clean and safe drinking water for the population. For specific prophylaxis, inactivated whole-virion vaccines already exist, while recombinant and live-attenuated vaccines are in active stages of development.